• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Precipio Inc.

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email
    SC 13G 1 e77479529.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*
     
    PRECIPIO, INC.
    (Name of Issuer)
     
    Common Stock, par value $0.01 per share
     
    (Title of Class of Securities)

     74019L107
     
    (CUSIP Number)
     
    July 25, 2024
     
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     


      
    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    David A. Eklund
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a) ☐
    (b) ☐
     
    3.
    SEC USE ONLY
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
     
    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    SOLE VOTING POWER
    84,250
     
    6.
    SHARED VOTING POWER
    0
     
    7.
    SOLE DISPOSITIVE POWER 
    84,250
     
    8.
    SHARED DISPOSITIVE POWER
    0
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    84,250
     
    10.
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions) ☐
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.73% (1)
     
    12.
    TYPE OF REPORTING PERSON (see instructions)
    IN
     
     

    (1)
    Based on 1,469,540 shares of Common Stock issued and outstanding as of May 9, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed on May 14, 2024.


    Item 1.
     
    (a)
    Name of Issuer
    Precipio, Inc.

     
    (b)
    Address of Issuer’s Principal Executive Offices
    4 Science Park
    New Haven, CT 06511
     
    Item 2.
     
    (a)
    Name of Person Filing
    David A. Eklund (“Reporting Person”)
     
     
    (b)
    Address of the Principal Office or, if none, residence
    The address of the principal office of Reporting Person is
    15322 Corsini Way
    Naples, FL 34110
     
     
    (c)
    Citizenship
    United States.
     
     
    (d)
    Title of Class of Securities
    Common Stock, par value $0.01 per share.
     
     
    (e)
    CUSIP Number
    74019L107



    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    (a)
    ☐
     Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
     
     
    (b)
    ☐
     Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
     
     
    (c)
    ☐
     Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
     
     
     
    (d)
    ☐
     Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
     
     
    (e)
    ☐
     An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
     
     
    (f)
    ☐
     An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
     
     
    (g)
    ☐
     A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
     
     
    (h)
    ☐
     A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
     
     
    (i)
    ☐
     A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
     
     
    (j)
    ☐
     Group, in accordance with §240.13d-1(b)(1)(ii)(J).
     
     
      


    Item 4. Ownership.
     
    (a)
     
    Amount beneficially owned:
     
    On July 25, 2024, the Reporting Person beneficially owned, in the aggregate, 84,250 shares of Common Stock, representing approximately 5.73% of the outstanding shares of Common Stock. The percentage in this paragraph and elsewhere in this Schedule 13G relating to beneficial ownership of Common Stock is based on 1,469,540 shares of Common Stock outstanding.
    59,250 shares of Common Stock reported herein as beneficially owned by the Reporting Person are held indirectly by DAJA Associates, LP (“Daja”).
    9,250 shares of Common Stock reported herein as beneficially owned by the Reporting Person are held indirectly by the Jeanine Eklund 2012 Trust (the “Trust”).
    15,750 shares of Common Stock reported herein as beneficially owned by the Reporting Person are held indirectly by David Eklund and Jeanine Eklund JTWROS (the “JT Account”).
    The Reporting Person controls all decisions with respect to the voting and disposition of the shares of Common Stock owned by each of Daja, the Trust and the JT Account.
     
     
    (b)
     
    Percent of class:
     
    5.73%
     
    (c)
     
    Number of shares as to which such person has:
     
     
     
    (i) Sole power to vote or to direct the vote:
     
    84,250
     
     
     
    (ii) Shared power to vote or to direct the vote:
     
    0
     
     
     
    (iii) Sole power to dispose or to direct the disposition of:
     
    84,250
     
     
     
    (iv) Shared power to dispose or to direct the disposition of:
     
    0

    Item 5. Ownership of Five Percent or Less of a Class.
     
    Not Applicable.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.
     
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
     
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
     
    Item 10. Certification.
     
    Not Applicable.



    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


    Dated August 1, 2024

       
      /s/ David A. Eklund                                            
     
    DAVID A. EKLUND
     
    Get the next $PRPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/26/26 4:00:15 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/21/26 4:00:21 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Valauri Christina Rizopoulos

    4 - Precipio, Inc. (0001043961) (Issuer)

    4/17/26 5:01:48 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precipio Announces Q1 2026 Financial Results

    NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn

    5/14/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Management team's 2025 market-based Options have vested

    NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted. As proposed by the Company's Compensation Committee in late 2024, rather than the standard 4-year time-based vesting period, management was offered and agreed to a market-based vesting structure whereby the options fully vest once the Company's share price exceeds a 10-day VWAP of $30.30. At the time of the grant, the share price and the options strike price w

    5/13/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q1-2026 Shareholder Update Call

    NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company's current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. As part of Precipio's ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company's performance, strat

    5/6/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:19:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    SEC Filings

    View All

    SEC Form 10-Q filed by Precipio Inc.

    10-Q - Precipio, Inc. (0001043961) (Filer)

    5/14/26 4:16:28 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    5/6/26 5:15:42 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Precipio Inc.

    DEFA14A - Precipio, Inc. (0001043961) (Filer)

    4/28/26 4:31:36 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Financials

    Live finance-specific insights

    View All

    Precipio Announces Q1 2026 Financial Results

    NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn

    5/14/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Management team's 2025 market-based Options have vested

    NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted. As proposed by the Company's Compensation Committee in late 2024, rather than the standard 4-year time-based vesting period, management was offered and agreed to a market-based vesting structure whereby the options fully vest once the Company's share price exceeds a 10-day VWAP of $30.30. At the time of the grant, the share price and the options strike price w

    5/13/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q1-2026 Shareholder Update Call

    NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company's current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. As part of Precipio's ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company's performance, strat

    5/6/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    View All

    Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    3/21/22 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    11/3/21 8:00:00 AM ET
    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    3/3/21 11:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Precipio Inc.

    SC 13G - Precipio, Inc. (0001043961) (Subject)

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials